Takeda Reports Results of Takhzyro (lanadelumab) in P-III (SPRING) Study for the Prevention of HAE Attacks in Children Aged 2 to <12 Years
Shots:
- The P-III (SPRING) study evaluate Takhzyro (150mg, q4w) in patients aged 2 & 6yrs. & q2w aged 6 & 12yrs. with HAE
- The results showed a ~95% reduction in the rate of HAE attacks vs baseline over 52wk., 76.2% were attack-free with an avg. of 99.5% attack-free days, 33.3% reported any TEAE related to treatment, no deaths, serious TEAEs, hospitalizations, or discontinuations due to TEAEs. The results were consistent with the favorable efficacy & safety profile of Takhzyro as observed in earlier studies
- Steady-state exposure with (150mg, q2w) was similar, minimum steady-state concentrations with (150mg, q4w) were 50–60% which produce a treatment response over adults & older adolescents with 300mg, q2w. The regulatory filings are expected to initiate in 2022
Ref: Takeda | Image: Takeda
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
